Intolerance of uncertainty in parents of childhood cancer survivors: A clinical profile analysis

Haegen, Marie Vander; Étienne, Anne-Marie

doi:10.1080/07347332.2018.1499692

Cited by 13 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, patients with cancer have a multidimensional etiology of mental health problems. The potentially life-threatening characteristic of cancer and the uncertainty related to its progression cancer might cause considerable psychological distress [ 4 , 5 ], with the fear of cancer recurrence and death also contributing to the stress [ 6 ]. Recent cellular and molecular studies have identified that biological processes involving the immune and endocrine systems mediate the association between psychological distress and cancer progression [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis

Yang

et al. 2021

Psychiatry Investig

View full text Add to dashboard Cite

Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms.Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model.Results Overall, five studies were included, revealing that psilocybin was superior to the placebo in treating state anxiety at 1 day (Hedges’ g, -0.70; 95% confidence interval, -1.01 to -0.39) and 2 weeks (-1.03; -1.47 to -0.60) after treatment. Psilocybin was more effective than placebo in treating trait anxiety at 1 day (-0.71; -1.15 to -0.26), 2 weeks (-1.08; -1.80 to -0.36), and 6 months (-0.84; -1.37 to -0.30) after treatment. Psilocybin was associated with transient elevation in systolic (19.00; 13.58–24.41 mm Hg) and diastolic (8.66; 5.18–12.15 mm Hg) blood pressure compared with placebo. The differences between psilocybin and placebo groups with regard to allcause discontinuation, serious adverse events, and heart rates were nonsignificant.Conclusion Psilocybin-assisted therapy could ameliorate end-of-life anxiety symptoms without serious adverse events. Because of the small sample sizes of the included studies and high heterogeneity on long-term outcomes, future randomized controlled trials with large sample sizes are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis

Yang

et al. 2021

Psychiatry Investig

View full text Add to dashboard Cite

show abstract

“…When successful in reducing distress and discomfort, the use of worry behaviors becomes negatively reinforced, helping to manage an intolerance of uncertainty in the long term [77,78]. This intolerance of uncertainty is a core feature of GAD and is common among parents of children treated for cancer [79].…”

Section: Worry Management For Gadmentioning

confidence: 99%

Internet-Administered Cognitive Behavioral Therapy for Common Mental Health Difficulties in Parents of Children Treated for Cancer: Intervention Development and Description Study

Woodford¹,

Farrand²,

Hagström³

et al. 2021

JMIR Form Res

View full text Add to dashboard Cite

Background Following the end of a child’s treatment for cancer, parents may report psychological distress. However, there is a lack of evidence-based interventions that are tailored to the population, and psychological support needs are commonly unmet. An internet-administered low-intensity cognitive behavioral therapy (LICBT)–based intervention (EJDeR [internetbaserad självhjälp för föräldrar till barn som avslutat en behandling mot cancer]) may provide a solution. Objective The first objective is to provide an overview of a multimethod approach that was used to inform the development of the EJDeR intervention. The second objective is to provide a detailed description of the EJDeR intervention in accordance with the Template for Intervention Description and Replication (TIDieR) checklist. Methods EJDeR was developed through a multimethod approach, which included the use of existing evidence, the conceptualization of distress, participatory action research, a cross-sectional survey, and professional and public involvement. Depending on the main presenting difficulty identified during assessment, LICBT behavioral activation or worry management treatment protocols are adopted for the treatment of depression or generalized anxiety disorder when experienced individually or when comorbid. EJDeR is delivered via the Uppsala University Psychosocial Care Programme (U-CARE) portal, a web-based platform that is designed to deliver internet-administered LICBT interventions and includes secure videoconferencing. To guide parents in the use of EJDeR, weekly written messages via the portal are provided by e-therapists comprising final year psychology program students with training in cognitive behavioral therapy. Results An overview of the development process and a description of EJDeR, which was informed by the TIDieR checklist, are presented. Adaptations that were made in response to public involvement are highlighted. Conclusions EJDeR represents a novel, guided, internet-administered LICBT intervention for supporting parents of children treated for cancer. Adopting the TIDieR checklist offers the potential to enhance fidelity to the intervention protocol and facilitate later implementation. The intervention is currently being tested in a feasibility study (the ENGAGE study). International Registered Report Identifier (IRRID) RR2-10.1136/bmjopen-2018-023708

show abstract

“…The Psycho Soma-Oncology Scale (PSOS, 20 ) is an 8-item self-report instrument that assesses psychosomatic symptoms; items are rated on a 5-point Likert scale (i.e., ranging from "1:Not at all typical of me" until "5: Very typical of me"). The PSOS examines six dimensions: insomnias, loss of energy, weight, gastrointestinal symptoms, headaches and sexual disorders.…”

Section: Psychological Distress: Somatic Symptoms Anxiety Depressiomentioning

confidence: 99%

Intolerance of uncertainty as the vulnerability factor among parents of childhood cancer survivors: A 3-month follow-up study

Haegen

Étienne

2018

Journal of Psychosocial Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Intolerance of uncertainty in parents of childhood cancer survivors: A clinical profile analysis

Cited by 13 publications

References 18 publications

Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis

Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis

Internet-Administered Cognitive Behavioral Therapy for Common Mental Health Difficulties in Parents of Children Treated for Cancer: Intervention Development and Description Study

Intolerance of uncertainty as the vulnerability factor among parents of childhood cancer survivors: A 3-month follow-up study

Contact Info

Product

Resources

About